OTLK Outlook Therapeutics

Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference

Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference

ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that of Outlook Therapeutics, will present at the being held virtually on Wednesday, August 17.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the .

A of the presentation will be accessible for viewing on-demand beginning on Wednesday, August 17, 2022, at 7:00 AM ET for those registered for the event and will be available on the page in the section of the Company’s website (). The webcast replay will be archived for 90 days following the event.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a pre-commercial biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. For more information, please visit .

CONTACTS:

Media Inquiries:

Harriet Ullman

Vice President

LaVoie Health Science

T: 617-669-3082

Investor Inquiries:       

Jenene Thomas

Chief Executive Officer

JTC Team, LLC

T: 833.475.8247 



EN
04/08/2022

Underlying

OTLKOutlook Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Outlook Therapeutics

 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healt...

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference Live webcast fireside chat on Tuesday, December 2nd at 10:00 AM ET ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that Bob Jahr, Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 10:00 AM ET. In addition to the fireside chat,...

November 24, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces Acceptance of Biologics License Applica...

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational oph...

November 13, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Re-Submits Biologics License Application for ONS-...

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, after receiving the official minutes from the FDA Type A meeting conducted in September 2025. ONS-5010 is an investigational ophthalmic formulation of bevacizumab which, if approved, will be br...

November 3, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Outlook Therapeutics Provides Update on Type A Meeting with FDA ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) --   (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has completed the Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet ...

September 29, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotli...

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris. Details for the presentations are as follows: Session: VEGF Related and Other Retinal Indications Title: Optimising the treatment of retinal diseasePresenter: of Outlook The...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch